SEER Inquiry System - Question 20021042 Details

System Guide

Back to Search Results

SEER Inquiry System - Report

Produced: 01/12/2025 10:32 AM

Question 20021042

Export CSV Export PDF Print

Add to Report

Inquiry Details

References:

2004 SEER Manual, 192-193

Question:

Hormone Therapy--Breast: Should Zoladex (gosrelin) or Lupron (leuprolide acetate) be coded as treatment for breast cancer when the physician does not indicate whether or not these drugs are intended as cancer-directed therapy? See discussion.

Discussion:

According to an oncologist at the research hospital in our region, these drugs are given in combination with chemotherapy for two reasons:

1) To preserve ovarian function.

2) The agents may be more effective in treating breast cancer when given in conjunction with chemotherapy than with chemotherapy alone.

Answer:

For cases diagnosed 1/1/2003 to 12/31/2010: Code Zoladex (gosrelin) and Lupron (leuprolide acetate) as 01 [Hormone therapy administered as first course therapy] only when stated to be given as part of the first course of cancer-directed therapy. If you do not know whether these drugs were given to preserve ovarian function or as an adjunct to chemotherapy (i.e, there is no treatment plan), do not code as Hormonal treatment given.

History:

For cases diagnosed prior to 2003: Cases coded using the SEER Program Code Manual 3rd Edition one digit hormone therapy codes must be converted to the two-digit scheme in Revision 1. Codes 82, 85, and 86 are invalid for cases diagnosed prior to 1/1/2003.

Cancer Site Category:

Breast

Data Item Category:

N/A

Other Category:

N/A

Year:

2002